Three companies completed public offerings on Wednesday,raising a total of $104 million.
Biomira Inc. raised $44 million in a secondary offering of 4million shares sold in the United States and Canada at $11(C$12.50) per share.
The stock (NASDAQ:BIOMF) closed Wednesday at $11.13, down13 cents.
The Edmonton, Alberta-based company, which is developingcancer diagnostics and therapeutics, has 17.4 million sharesoutstanding after the offering. ScotiaMcLeod Inc. andScotiaMcLeod U.S.A. Inc. are the underwriters.
DNX Corp. completed its initial public offering of 2.5 millionshares at $13 per share, the low end of its $13 to $15 per shareprice range.
The stock (NASDAQ:DNXX) closed unchanged Wednesday at$12.50.
The company, which raised $12.1 million in second-roundventure financing in September, is developing transgenicanimals to produce human therapeutics, such as humanhemoglobin for use as a blood substitute and human serumalbumin as a blood volume expander. DNX also providesbiological testing services through its Pharmakon ResearchInternational Inc. subsidiary.
After the offering, the Princeton, N.J., company has 9 millionshares outstanding. Underwriters Hambrecht & Quist Inc. andOppenheimer & Co. have a 375,000-share overallotment option.
Vertex Pharmaceuticals Inc. raised $27.5 million through asecondary offering of 2 million shares priced at $13.75. Afterthe offering, the Cambridge, Mass., rational drug designcompany has 11.8 million shares outstanding.
In July, Vertex raised $27 million in a 3 million-share IPOpriced at $9. The company had proposed a $13 to $15 pricerange, but reduced the price due to market conditions.
Underwriters for the U.S. offering, Kidder, Peabody & Co. Inc.and Cowen & Co., have a 300,000-share overallotment option.Kidder, Peabody International Ltd. and Cowen are internationalunderwriters.
The stock (NASDAQ:VRTX) closed at $14, up 13 cents.
(c) 1997 American Health Consultants. All rights reserved.